Abstract

The objective of this work was to study the effect of Gentabiferon-B on the morphofunctional state of the organism of mice with Ehrlich ascites carcinoma (EAC) under the effect of doxorubicin. We studied the individual and combined effects of drugs on the concentration of tumor cells in the peritoneal cavity, as well as leukocytes and their individual populations in the blood of mice with EAC on day 10 of tumor growth; in addition, the longevity in the animals with a tumor was estimated after the use of doxorubicin and Gentabiferon-B. It was established that the combined use of drugs did not reduce the specific cytotoxic effect of doxorubicin in relation to tumor cells, which was assessed by the concentration of EAC cells in ascite. The number of tumor cells in the animals of this group was by 49.3% lower than the concentration of neoplasm cells in mice with EAC without treatment. In the experiment, an increase by 55.8% in the life expectancy of the animals treated with doxorubicin and Gentabiferon-B was observed relative to mice with a tumor after monotherapy with Gentabiferon-B. Combined drug therapy induced an increase in the concentration of blood lymphocytes by 39.5% relative to the number of these cells in mice with EAC after exposure to doxorubicin alone. The results obtained allows to assume that the efficacy of the antitumor activity of doxorubicin in its combined use with Gentabiferon-B and the immunomodulatory effect of Gentabiferon-B in conditions of tumor progression are preserved.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.